Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ginger + ibuprofen is a combination product developed by Ferrosan AS, consisting of the non-steroidal anti-inflammatory drug (NSAID) ibuprofen and an extract of ginger (Zingiber officinale). It was investigated for the treatment of chronic back pain to improve joint health and quality of life. Ibuprofen functions as a non-selective inhibitor of cyclooxygenase enzymes (COX-1 and COX-2), which reduces the synthesis of pro-inflammatory prostaglandins. Ginger contains bioactive compounds such as gingerols and shogaols that are believed to inhibit both the cyclooxygenase and lipoxygenase (5-LOX) pathways, potentially offering a synergistic anti-inflammatory effect. The combination was evaluated in a Phase 2 clinical trial (NCT00445757) over a 12-week period.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ginger + ibuprofen.